Ausgabe 5/2012
Inhalt (31 Artikel)
Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts
Mahmoud Alhosin, Abdulkhaleg Ibrahim, Abdelaziz Boukhari, Tanveer Sharif, Jean-Pierre Gies, Cyril Auger, Valérie B. Schini-Kerth
A synthetic decursin analog with increased in vivo stability suppresses androgen receptor signaling in vitro and in vivo
Yong Zhang, Ahmad Ali Shaik, Chengguo Xing, Yubo Chai, Li Li, Jinhui Zhang, Wei Zhang, Sung-Hoon Kim, Junxuan Lü, Cheng Jiang
The cytotoxic activity of Aplidin in chronic lymphocytic leukemia (CLL) is mediated by a direct effect on leukemic cells and an indirect effect on monocyte-derived cells
Pablo E. Morande, Samanta R. Zanetti, Mercedes Borge, Paula Nannini, Carolina Jancic, Raimundo F. Bezares, Alicia Bitsmans, Miguel González, Andrea L. Rodríguez, Carlos M. Galmarini, Romina Gamberale, Mirta Giordano
Cluvenone induces apoptosis via a direct target in mitochondria: a possible mechanism to circumvent chemo-resistance?
Gianni Guizzunti, Emmanuel A. Theodorakis, Alice L. Yu, Chiara Zurzolo, Ayse Batova
The effect of a novel frizzled 8-related antiproliferative factor on in vitro carcinoma and melanoma cell proliferation and invasion
Kristopher R. Koch, Chen-Ou Zhang, Piotr Kaczmarek, Joseph Barchi Jr., Li Guo, Hanief M. Shahjee, Susan Keay
Identification of a novel class of anti-inflammatory compounds with anti-tumor activity in colorectal and lung cancers
Hui-Hua Chang, Zuohe Song, Lee Wisner, Tina Tripp, Vijay Gokhale, Emmanuelle J. Meuillet
Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors
Yoshihiko Fujita, Rafiqul Islam, Kazuko Sakai, Hiroyasu Kaneda, Kanae Kudo, Daisuke Tamura, Keiichi Aomatsu, Tomoyuki Nagai, Hidekazu Kimura, Kazuko Matsumoto, Marco A. de Velasco, Tokuzo Arao, Tadashi Okawara, Kazuto Nishio
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells
Ji Hye Park, Mee Young Ahn, Tae Hyung Kim, Sungpill Yoon, Keon Wook Kang, Jaewon Lee, Hyung Ryong Moon, Jee H. Jung, Hae Young Chung, Hyung Sik Kim
ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities
Frankie Lam, Tracey D. Bradshaw, Hui Mao, Scott Roberts, Yuanjiang Pan, Shudong Wang
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
Auke D. Adema, Kees Smid, Nienke Losekoot, Richard J. Honeywell, Henk M. Verheul, Finn Myhren, Marit L. Sandvold, Godefridus J. Peters
The nucleoside antagonist cordycepin causes DNA double strand breaks in breast cancer cells
Hong Jue Lee, Petra Burger, Marianne Vogel, Klaus Friese, Ansgar Brüning
Eribulin mesylate in patients with refractory cancers: a Phase I study
Toru Mukohara, Shunji Nagai, Hirofumi Mukai, Masayuki Namiki, Hironobu Minami
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors
Alan H. Bryce, Ravi Rao, Jann Sarkaria, Joel M. Reid, Yingwei Qi, Rui Qin, C. David James, Robert B. Jenkins, Joseph Boni, Charles Erlichman, Paul Haluska
Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies
Lia Gore, E. Rivera, M. Basche, S. L. Moulder-Thompson, J. Li, S. Eppers, S. Grolnic, C. O’Bryant, D. Cleere, Y. A. Elsayed, S. G. Eckhardt
Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
Sachi Morita, Satoshi Oizumi, Hironobu Minami, Koichi Kitagawa, Yoshito Komatsu, Yutaka Fujiwara, Megumi Inada, Satoshi Yuki, Naomi Kiyota, Ayako Mitsuma, Masataka Sawaki, Hiromi Tanii, Junko Kimura, Yuichi Ando
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors
Andrea Wang-Gillam, William P. Tew, Mace L. Rothenberg, Jakob Dupont, Wendy Cooper, Lars Sternas, Giliane Buzenet, Jeffrey A. Sosman, David R. Spriggs, Albert Craig Lockhart
Phase I open-label study of cediranib, an oral inhibitor of VEGF signalling, in combination with the oral Src inhibitor saracatinib in patients with advanced solid tumours
Tanja Trarbach, Beate Schultheis, Thomas C. Gauler, Vesile Schneider, Dirk Strumberg, Wilfried E. E. Eberhardt, Stephanie Le Scouiller, Marcelo Marotti, Kathryn H. Brown, Joachim Drevs
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer
In Hae Park, Keun Seok Lee, Han-Sung Kang, Seok Won Kim, Seeyoun Lee, So-Youn Jung, Youngmee Kwon, Kyung Hwan Shin, Kyounglan Ko, Byung-Ho Nam, Jungsil Ro
Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study
Gerardo Rosati, Stefano Cordio, Giuseppe Aprile, Alfredo Butera, Antonio Avallone, Giuseppe Di Lucca, Federica De Pauli, Hector Soto Parra, Giorgio Reggiardo, Roberto Bordonaro
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum
Jae-Lyun Lee, Jin-Hee Ahn, Se Hoon Park, Ho Young Lim, Jung Hye Kwon, Shin Ahn, Cheryn Song, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
Saturable absorption of sorafenib in patients with solid tumors: a population model
Marilyne Hornecker, Benoit Blanchet, Bertrand Billemont, Hind Sassi, Stanislas Ropert, Fabrice Taieb, Olivier Mir, Halim Abbas, Laura Harcouet, Romain Coriat, Alain Dauphin, François Goldwasser, Michel Tod
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors
Thomas J. Semrad, Courtney Eddings, Chong-Xian Pan, Derick H. Lau, David Gandara, Laurel Beckett, Primo N. Lara Jr
Nilotinib in patients with metastatic melanoma harboring KIT gene aberration
Jin Hyun Cho, Kyoung Mee Kim, Miyeon Kwon, Jung Han Kim, Jeeyun Lee
A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
Takuji Okusaka, Hiroshi Kasugai, Hiroshi Ishii, Masatoshi Kudo, Michio Sata, Katsuaki Tanaka, Yasukazu Shioyama, Kazuaki Chayama, Hiromitsu Kumada, Masaharu Yoshikawa, Toshihito Seki, Hidetugu Saito, Naoaki Hayashi, Keiko Shiratori, Kiwamu Okita, Isao Sakaida, Masao Honda, Yukio Kusumoto, Takuya Tsutsumi, Kenji Sakata
A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer
Natsuko T. Okita, Taito Esaki, Eishi Baba, Daisuke Sakai, Shinya Tokunaga, Hiroya Takiuchi, Nobuyuki Mizunuma, Kengo Nagashima, Ken Kato
First case of posterior reversible encephalopathy syndrome associated with vinflunine
Carole Helissey, Cyrus Chargari, Marion Lahutte, Damien Ricard, Lionel Vedrine, Bernard Ceccaldi, Sylvestre Le Moulec
Therapeutic reactivation of mutant p53 protein by quinazoline derivatives
Hamish S. Sutherland, In Young Hwang, Elaine S. Marshall, Brent S. Lindsay, William A. Denny, Catherine Gilchrist, Wayne R. Joseph, Debra Greenhalgh, Emma Richardson, Philip Kestell, Angela Ding, Bruce C. Baguley
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
Jennifer Arrondeau, Olivier Mir, Pascaline Boudou-Rouquette, Romain Coriat, Stanislas Ropert, Guillaume Dumas, Manuel J. Rodrigues, Benoit Rousseau, Benoit Blanchet, François Goldwasser
Continuing pursuit for ideal systemic anticancer radiotherapeutics
Marlein Miranda Cona, Huaijun Wang, Junjie Li, Yuanbo Feng, Feng Chen, Peter de Witte, Alfons Verbruggen, Yicheng Ni
Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
Roger B. Cohen, Stéphane Oudard
Potential mucolytic agents for mucinous ascites from pseudomyxoma peritonei
Krishna Pillai, Javed Akhter, Terence C. Chua, David L. Morris